TP53 and non-small cell lung carcinoma: The optimized Ku-DBi 3392 displayed similar activities in the p53-null H1299 NSCLC cell line, which remained highly resistant to the Ku-DBi treatment, and the A549 adenocarcinoma cells, which remained only slightly sensitive.